View More View Less
  • 1 Szegedi Tudományegyetem, Általános Orvostudományi Kar, Szeged, Semmelweis u. 8., 6725
  • | 2 Szegedi Tudományegyetem, Általános Orvostudományi Kar, Szeged
Restricted access

Cross Mark

Absztrakt:

A szisztémás amyloidosis ritka betegség, amelyben a szívérintettség viszonylag gyakran fordul elő és a túlélést jelentősen befolyásolja. Az alapbetegség és a szervi érintettség szempontjából új diagnosztikus eljárások segítenek a korai diagnózis felállításában és a mihamarabbi kezelés megkezdésében. Szívérintettség inkább a monoklonális immunglobulin-könnyűlánc (AL-amyloidosis) és a transthyretin formában fordul elő. AL-amyloidosis esetén a szívérintettség súlyos következményekhez vezet. A kezdeti súlyosság megítélésében és a kezelésre adott válasz mértékének mérésében a szívfunkcióval kapcsolatos biomarker-vizsgálatok segítenek. Amyloidosis esetén az életkorral nő a szívérintettség, a prevalencia nem ismert pontosan, de feltételezhető, hogy több eset van valójában, mint amennyi felismerésre kerül. A szerzők a klinikai tünetek, diagnosztikus eljárások, kiemelten a kardiológiai vizsgálatok jelentőségét ismertetik. Orv Hetil. 2017; 158(46): 1811–1818.

  • 1

    Sipe JD, Benson MD, Buxbaum JN, et al. Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid 2014; 21: 221–224.

  • 2

    Esplin BL, Gertz MA. Current trends in diagnosis and management of cardiac amyloidosis. Curr Probl Cardiol. 2013; 38: 53–96.

  • 3

    Pepys MB, Rademacher TW, Amatayakul-Chantler S, et al. Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure. Proc Natl Acad Sci. USA 1994; 91: 5602–5606.

  • 4

    Tan SY, Pepys MB. Amyloidosis. Histopathology 1994; 25: 403–414.

  • 5

    Merlini G. CyBorD: stellar response rates in AL amyloidosis. Blood 2012; 119: 4343–4345.

  • 6

    Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007; 356: 2361–2371.

  • 7

    Liao R, Jain M, Teller P, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 2001; 104: 1594–1597.

  • 8

    Shi J, Guan J, Jiang B, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci. USA 2010; 107: 4188–4193.

  • 9

    Merlini G, Lousada I, Ando Y, et al. Rationale application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Leukemia 2016; 30: 1979–1986.

  • 10

    Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012; 30: 989–995.

  • 11

    Grogan M, Dispenzieri A, Gertz MA. Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response. Heart 2017; 103: 1065–1072.

  • 12

    Dispenzieri A, Dingli D, Kumar SK, et al. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs. Am J Hematol. 2010; 85: 757–759.

  • 13

    Palladini G, Foli A, Milani P, et al. Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure. Am J Hematol. 2012; 87: 465–471.

  • 14

    Cheng ZW, Tian Z, Kang L, et al. Electrocardiographic and echocardiographic features of patients with primary cardiac amyloidosis. Zhonghua Xin Xue Guan Bing Za Zhi 2010; 38: 606–609.

  • 15

    Murtagh B, Hammill SC, Gertz MA, et al. Electrocardiographic findings in primary systemic amyloidosis and biopsy-proven cardiac involvement. Am J Cardiol. 2005; 95: 535–537.

  • 16

    Patel AR, Dubrey SW, Mendes LA, et al. Right ventricular dilation in primary amyloidosis: an independent predictor of survival. Am J Cardiol. 1997; 80: 486–492.

  • 17

    Porciani MC, Lilli A, Perfetto F, et al. Tissue Doppler and strain imaging: a new tool for early detection of cardiac amyloidosis. Amyloid 2009; 16: 63–70.

  • 18

    Tsang W, Lang RM. Echocardiographic evaluation of cardiac amyloid. Curr Cardiol Rep. 2010; 12: 272–276.

  • 19

    Bellavia D, Pellikka PA, Abraham TP, et al. Evidence of impaired left ventricular systolic function by Doppler myocardial imaging in patients with systemic amyloidosis and no evidence of cardiac involvement by standard two-dimensional and Doppler echocardiography. Am J Cardiol. 2008; 101: 1039–1045.

  • 20

    Falk RH, Alexander KM, Liao R, et al. AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol. 2016; 68: 1323–1341.

  • 21

    Sengupta PP, Tajik AJ, Chandrasekaran K, et al. Twist mechanics of the left ventricle: principles and application. JACC Cardiovasc Imaging 2008; 1: 366–376.

  • 22

    Nemes A, Kalapos A, Domsik P, et al. Left ventricular rotation and twist of the heart. [A szív bal kamrai rotációja és csavarodása.] Orv Hetil. 2012; 153: 1547–1551. [Hungarian]

  • 23

    Ammar KA, Paterick TE, Khandheria BK, et al. Myocardial mechanics: understanding and applying three-dimensional speckle tracking echocardiography in clinical practice. Echocardiography 2012; 29: 861–872.

  • 24

    Nemes A, Kalapos, A, Domsik P, et al. Three-dimensional speckle-tracking echocardiography – a further step in the non-invasive three-dimensional cardiac imaging. [Háromdimenziós speckle-tracking echokardiográfia – egy újabb lépés a noninvazív háromdimenziós cardialis képalkotásban.] Orv Hetil. 2012; 153: 1570–1577. [Hungarian]

  • 25

    Nemes A, Földeák D, Domsik P, et al. Different patterns of left ventricular rotational mechanics in cardiac amyloidosis-results from the three-dimensional speckle-tracking echocardiographic MAGYAR-Path Study. Quant Imaging Med Surg. 2015; 5: 853–857.

  • 26

    Vogelsberg H, Mahrholdt H, Deluigi CC, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol. 2008; 51: 1022–1030.

  • 27

    Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation 2005; 111: 186–193.

  • 28

    Banypersad SM, Moon JC, Whelan C, et al. Updates in cardiac amyloidosis: a review. J Am Heart Assoc. 2012; 1: e000364.

  • 29

    Wechalekar A, Schonland SO, Kastritis E, et al. European collaborative study of treatment outcomes in 347 patients with systemic AL amyloidosis with Mayo stage III disease. Blood 2011; 118: 995.

  • 30

    Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004; 22: 3751–3757.

  • 31

    Palladini G, Barassi A, Klersy C, et al. The combination of high-sensitivity cardiac troponin T (hs-cTnT) at presentation and changes in N-terminal natriuretic peptide type B (NT-proBNP) after chemotherapy best predicts survival in AL amyloidosis. Blood 2010; 116: 3426–3430.

  • 32

    Kristen AV, Giannitsis E, Lehrke S, et al. Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay. Blood 2010; 116: 2455–2461.

  • 33

    Dispenzieri A, Lacy MQ, Katzmann JA, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2006; 107: 3378–3383.

  • 34

    Palladini G, Dispenzieri A, Gertz MA, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012; 30: 4541–4549.

  • 35

    Sousa M, Monohan G, Rajagopalan N, et al. Heart transplantation in cardiac amyloidosis. Heart Fail Rev. 2017; 22: 317–327.

  • 36

    Gertz MA, Lacy MQ, Dispenzieri A, et al. Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med. 2002; 113: 549–555.

  • 37

    Comenzo RL, Reece D, Palladini G, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 2012; 26: 2317–2325.

  • 38

    Gertz MA, Lacy MQ, Dispenzieri A, et al. Trends in day 100 and 2-year survival after auto-SCT for AL amyloidosis: outcomes before and after 2006. Bone Marrow Transplant. 2011; 46: 970–975.

  • 39

    Gertz MA, Lacy MQ, Dispenzieri A, et al. Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis. Bone Marrow Transplant. 2013; 48: 557–561.

  • 40

    Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002; 99: 4276–4282.

  • 41

    Wechalekar AD, Goodman HJ, Lachmann HJ, et al. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007; 109: 457–464.

  • 42

    Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004; 103: 2936–2938.

  • 43

    Venner CP, Lane T, Foard D, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 2012; 119: 4387–4390.

  • 44

    Mikhael JR, Schuster SR, Jimenez-Zepeda VH, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012; 119: 4391–4394.

  • 45

    Moreau P, Jaccard A, Benboubker L, et al. Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood 2010; 116: 4777–4782.

  • 46

    Kastritis E, Terpos E, Roussou M, et al. A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood 2012; 119: 5384–5390.

  • 47

    Palladini G, Russo P, Milani P, et al. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica 2013; 98: 433–436.

  • 48

    Gertz MA, Dispenzieri A. Immunoglobulin light-chain amyloidosis: growing recognition, new approaches to therapy, active clinical trials. Oncology 2012; 26: 152–161.

  • 49

    Landau H, Hassoun H, Rosenzweig MA, et al. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia 2013; 27: 823–828.

  • 50

    Sanchorawala V, Brauneis D, Shelton AC, et al. Induction therapy with bortezomib followed by bortezomib-high dose melphalan and stem cell transplantation for light chain amyloidosis: results of a prospective clinical trial. Biol Blood Marrow Transplant. 2015; 21: 1445–1451.

  • 51

    Kristen AV, Dengler TJ, Hegenbart U, et al. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm 2008; 5: 235–240.

All Time Past Year Past 30 Days
Abstract Views 129 129 2
Full Text Views 32 22 0
PDF Downloads 22 19 0